The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

Mon, 18th Dec 2023 16:55

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

The FTSE 100 index closed up 38.12 points, 0.5%, at 7,614.48. The FTSE 250 ended up 11.58 points, 0.1%, at 19,220.55, and the AIM All-Share closed up 1.88 points, or 0.3%, at 741.19.

The Cboe UK 100 ended up 0.5% at 760.32, the Cboe UK 250 closed up 0.1% at 16,679.25, and the Cboe Small Companies ended up 0.5% at 14,370.59.

In European equities on Monday, the CAC 40 in Paris ended down 0.4%, while the DAX 40 in Frankfurt ended down 0.6%.

On Monday, markets were digesting some hawkish comments from US Federal Reserve officials.

This is a move away from Wednesday's pivot, when the Fed left US interest rates unchanged, but signalled for cuts in 2024.

New York Federal Reserve President John Williams told CNBC's 'Squawk Box' that the central bank isn't "really talking about rate cuts right now".

Separately, Atlanta Fed President Raphael Bostic, who votes on monetary policy next year, told Reuters that he expects two rate cuts in 2024 but not starting until the third quarter. Meanwhile, Loretta Mester, the president of Cleveland Fed, said markets are a "bit ahead" of central bank on rate cuts.

AJ Bell's Russ Mould said the comments has left markets "somewhat in limbo."

Still to come this week, there are US gross domestic product readings, as well as core inflation figures. The data could give investors more guidance about where interest rates might go.

Stocks in New York were higher at the London equities close, with the DJIA up 0.2%, the S&P 500 index up 0.5%, and the Nasdaq Composite up 0.4%.

The pound was quoted at USD1.2640 at the London equities close Monday, lower compared to USD1.2693 at the close on Friday. The euro stood at USD1.0914 at the European equities close Monday, slightly higher against USD1.0912 at the same time on Friday.

We still aren't done with interest rates decision for 2023. The Bank of Japan announces its monetary policy on Tuesday.

According to a Bloomberg report last Monday citing "people familiar with the matter", the BoJ is likely to keep its ultra-loose monetary policy in place, despite recent market speculation that the negative rate may be scrapped.

Against the yen, the dollar was trading at JPY143.05, higher compared to JPY141.75 late Friday.

In the FTSE 100, BP rose 1.6%.

The oil firm said it had joined other companies in suspending transits through the Red Sea, after Yemen's Huthi rebels targeted Israel with missiles.

"In light of the deteriorating security situation for shipping in the Red Sea, BP has decided to temporarily pause all transits," a statement said.

"We will keep this precautionary pause under ongoing review, subject to circumstances as they evolve in the region," it added.

SPI Asset Management's Stephen Innes explained: "It appears that a cohort of traders are taking hedging precautions against the tail risk associated with the Strait of Hormuz, which is providing the bid today. The Houthis' focus on vessels with ties to Israeli ownership or those engaged in shipping cargo to Israel through the Red Sea has raised concerns."

Peer Shell rose 1.4%.

Brent oil was quoted at USD78.52 a barrel at the London equities close Monday, up from USD76.34 late Friday.

At the top of the index was Entain, up 4.1%. Jefferies raised the stock to 'buy' from 'hold'.

On the other hand, Fresnillo closed down 5.2%. Morgan Stanley cut the miner's stock to 'underweight' from 'equal-weight'. Housebuilders Berkeley Group and Barratt Developments were also stung by a broker downgrade, falling 3.4% and 2.5% respectively after UBS cut the stocks to 'neutral' from 'buy'.

In the FTSE 250 index, IP Group jumped 5.9%.

The investors launched a share buyback worth up to GBP20 million. The programme will run until the end of 2024.

"The board remains committed to making regular cash returns to shareholders from realisations," IP Group said.

On London's AIM, N4 Pharma surged 39%.

The pharmaceutical company announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Chief Executive Officer Nigel Theobald said: "This continued success shows that Nuvec has the potential to be successfully used as an oral delivery system with many potential applications such as a vaccine, a product for irritable bowel disease or to treat colonic cancer among many possible examples. Given the complexities involved in oral delivery this early success with Nuvec represents a potentially massive opportunity and point of difference for Nuvec and its use as delivery system to target multiple diseases."

Cap-XX plummeted 57%, after it responded to a court decision regarding its patent infringement case against Maxwell Technologies.

The Sydney-based company, which manufactures supercapacitors for portable electronic devices, started its patent infringement trial against Maxwell Technologies last Monday.

The complaint, filed in September 2019, alleged that Maxwell Technologies had directly and indirectly infringed on Cap-XX's patents for several capacitor products.

On Friday, the jury in the Delaware district court affirmed that Cap-XX's patents were invalid, thereby nullifying the accusations against Maxwell. As a result, Maxwell is not liable to pay any damages or license fees.

Gold was quoted at USD2,022.88 an ounce at the London equities close Monday, lower against USD2,034.62 at the close on Friday.

In Tuesday's UK corporate calendar, there is a consumer price index for the eurozone at 1000 GMT.

The economic calendar for has half year results from Hipgnosis Songs Fund. There is a trading statement from Nanoco.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Mar 2021 16:31

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 Feb 2021 12:34

N4 Pharma losses widen as it works on commercialising Nuvec

(Sharecast News) - Pre-revenue specialist pharmaceuticals company N4 Pharma reported an operating loss of £1.56m in its final results on Wednesday, widening from the £0.95m loss a year earlier.

Read more
24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Read more
24 Feb 2021 10:03

N4 Pharma Loss Widens As Ramps Up R&D Investment At "Pivotal Time"

N4 Pharma Loss Widens As Ramps Up R&D Investment At "Pivotal Time"

Read more
11 Feb 2021 11:53

N4 Pharma Shares Jump On European Patent Approval For Nuvec

N4 Pharma Shares Jump On European Patent Approval For Nuvec

Read more
11 Feb 2021 11:21

AIM WINNERS & LOSERS: MediaZest Soars As Kicks Off 2021 With Deal Wins

AIM WINNERS & LOSERS: MediaZest Soars As Kicks Off 2021 With Deal Wins

Read more
9 Dec 2020 14:04

IN BRIEF: N4 Pharma Raises GBP2 Million To Fund Development Work

IN BRIEF: N4 Pharma Raises GBP2 Million To Fund Development Work

Read more
4 Dec 2020 10:33

UK WINNERS & LOSERS SUMMARY: Cineworld Falls On Warner Streaming Plans

UK WINNERS & LOSERS SUMMARY: Cineworld Falls On Warner Streaming Plans

Read more
3 Dec 2020 13:39

N4 Pharma shares surge on latest from Nanomerics collaboration

(Sharecast News) - Specialist pharmaceuticals company N4 Pharma updated the market on its ongoing research collaboration agreement with Nanomerics on Thursday.

Read more
3 Dec 2020 10:40

N4 Pharma Shares Soar As Cancer Drug Moves To Phase Two Of Programme

N4 Pharma Shares Soar As Cancer Drug Moves To Phase Two Of Programme

Read more
9 Nov 2020 14:22

N4 Pharma working with Nanomerics on oncology programme

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed Nanomerics to investigate the potential utility of its 'Nuvec' delivery system in cancer therapy.

Read more
9 Nov 2020 14:20

N4 Pharma Plans Nuvec Oncology Treatment Study With UCL's Nanomerics

N4 Pharma Plans Nuvec Oncology Treatment Study With UCL's Nanomerics

Read more
5 Nov 2020 18:07

UK TRADING UPDATE SUMMARY: Zotefoams Hails Record Third Quarter Sales

UK TRADING UPDATE SUMMARY: Zotefoams Hails Record Third Quarter Sales

Read more
17 Sep 2020 14:36

IN BRIEF: N4 Pharma Pretax Loss Widens; Aims To Maximise Nuvec Uses

IN BRIEF: N4 Pharma Pretax Loss Widens; Aims To Maximise Nuvec Uses

Read more
14 Sep 2020 10:52

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.